← Evidence map

ArticlePharmaceuticals (Basel, Switzerland)2026

XMU-MP-1, the Hippo Signaling Pathway MST-1 Kinase Inhibitor, Prevents the Development of Drug Resistance to Doxorubicin in Hematological Tumor Cells.

Alexander G Stepchenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

XMU-MP-1, the Hippo Signaling Pathway MST-1 Kinase Inhibitor, Prevents the Development of Drug Resistance to Doxorubicin in Hematological Tumor Cells. | OpenQuestion